Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Gonorrhoea

Essential points for quick revision.

Saved on this device
!
Disseminated or ocular infection

Fever with migratory arthralgia, tenosynovitis, pustular lesions or a hot joint suggests disseminated gonococcal infection, while severe purulent conjunctivitis threatens corneal integrity.

Action: Obtain blood, joint, mucosal or ocular cultures promptly, admit for parenteral specialist therapy, drain septic arthritis when required, and involve ophthalmology immediately for ocular disease.

Synopsis

Recognise gonorrhoea at genital and extragenital sites, secure culture for resistance surveillance, prescribe ceftriaxone correctly, and target test of cure and partner care.

  • Sample every exposed anatomical site by NAAT and obtain culture from each suspected or NAAT-positive site before treatment whenever this causes no unsafe delay.
  • The 2025 guideline recommends pharyngeal testing for every person with urogenital gonorrhoea and every gonorrhoea contact, even without reported oral exposure.
  • Treat uncomplicated anogenital or pharyngeal gonorrhoea with ceftriaxone 1 g intramuscularly once when susceptibility is unknown.

Key red flags

A painful swollen joint, fever, tenosynovitis or sparse pustular rash requires urgent assessment for disseminated gonococcal infection.

Hyperacute purulent conjunctivitis, eye pain, photophobia or visual change can progress to corneal perforation and needs emergency ophthalmology.

Pelvic pain with cervical motion or adnexal tenderness requires immediate broad PID treatment in addition to gonococcal coverage.

Sudden severe scrotal pain remains testicular torsion until assessed even when urethral discharge suggests infection.

Persistent symptoms or a positive post-treatment test may signal reinfection or antimicrobial failure and needs culture plus specialist resistance action. For symptomatic test-of-cure assessment, take culture at least 72 hours after treatment; in an asymptomatic patient use NAAT at least two weeks after treatment and culture any positive result.

Disseminated syndrome

Fever, migratory arthralgia, tendon-sheath pain, sparse pustules or septic monoarthritis suggests bloodstream spread and demands admission.

Ocular emergency

Copious purulent discharge with severe conjunctival inflammation can rapidly injure the cornea and requires urgent ophthalmological care.

Investigation priorities

01
Site-specific gonorrhoea NAATFirst step

Detect N. gonorrhoeae sensitively from genital, rectal and pharyngeal sites selected by diagnosis and exposure.

Management branches

SAMPLESecure sites and susceptibility

Symptoms, screening or contact notification creates clinical suspicion of gonorrhoea.

  1. Record exposure sites and timing, symptoms, pregnancy, previous antibiotics, allergy and any travel or prior resistant infection.
  2. Take genital, rectal and pharyngeal NAAT as indicated, always adding a pharyngeal sample for a urogenital diagnosis or contact.

Key medicines

CeftriaxoneGive 1 g by intramuscular injection as a single dose for uncomplicated anogenital or pharyngeal gonorrhoea.Check severe beta-lactam allergy, take cultures first where feasible, and arrange test of cure whenever site, pregnancy, symptoms or susceptibility requires it.
CiprofloxacinGive 500 mg orally once only when the isolate is susceptible and current specialist guidance supports its use.Review pregnancy, tendon, neurological, psychiatric, vascular, glycaemic and interacting-medicine risks under current fluoroquinolone restrictions.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom